Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Neumora Therapeutics, Inc.NMRA · Entity 6115 | See Remarks | August 20, 2026 | August 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Neumora Therapeutics, Inc.
Report date August 20, 2026 · Filed August 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.52 · Expires 2036-08-20 | Direct | 375,000 |
Reported balance
After 2026-08-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-20 · Grant · Acquired 375,000 · Balance 375,000 F1: 25% of the shares subject to the option vest on the first anniversary measured from August 20, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the option vest on the first anniversary measured from August 20, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ALBIREO PHARMA, INC.
Report date March 02, 2023 · Filed March 02, 2023
Section 16 reporting ended · disclosed 2023-03-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 1
1 source rowRow 1 · 2023-03-02 · Other · Disposed 3,296 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the "Merger Agreement"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation ("Parent"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee ("Guarantor"), and the Issuer, pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of March 2, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was canceled and converted into the right to receive $42.00 in cash, without interest (the "Closing Amount") F2: (Continued from Footnote 1) plus one non-tradeable contractual contingent value right ("CVR" and each CVR together with the Closing Amount, the "Offer Price"), which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement (the "CVR Agreement") on or prior to December 31, 2027 (the "Milestone"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.75 · Expires 2032-01-17 | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-03-02 · Disposition to issuer · Disposed 15,900 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement (a) each outstanding option to purchase Shares (each, a "Company Option") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an "In the Money Option"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an "Out of the Money Option") F4: (Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.04 · Expires 2029-01-21 | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-03-02 · Disposition to issuer · Disposed 10,063 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement (a) each outstanding option to purchase Shares (each, a "Company Option") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an "In the Money Option"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an "Out of the Money Option") F4: (Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.67 · Expires 2030-01-20 | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-03-02 · Disposition to issuer · Disposed 24,337 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement (a) each outstanding option to purchase Shares (each, a "Company Option") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an "In the Money Option"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an "Out of the Money Option") F4: (Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.88 · Expires 2031-01-20 | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-03-02 · Disposition to issuer · Disposed 23,700 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement (a) each outstanding option to purchase Shares (each, a "Company Option") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an "In the Money Option"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an "Out of the Money Option") F4: (Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.68 · Expires 2028-06-07 | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-03-02 · Disposition to issuer · Disposed 37,500 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement (a) each outstanding option to purchase Shares (each, a "Company Option") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an "In the Money Option"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an "Out of the Money Option") F4: (Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-03-02 · Disposition to issuer · Disposed 65,850 · Balance 0 F5: Each restricted stock unit represents a contingent right to receive one Share. F6: Pursuant to the terms of the Merger Agreement, (a) each outstanding restricted stock unit (each, a "Company RSU") that was granted prior to the date of the Merger Agreement, and each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as an "Accelerated 2023 RSU," was canceled and converted into the right to receive (1) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such Company RSU immediately prior to the Effective Time multiplied by (y) $42.00 and (2) one CVR for each Share subject to such Company RSU immediately prior to the Effective Time; and (b) each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as a "Cancelled 2023 RSU" was canceled and had no further force or effect. F7: Not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the "Merger Agreement"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation ("Parent"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee ("Guarantor"), and the Issuer, pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of March 2, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was canceled and converted into the right to receive $42.00 in cash, without interest (the "Closing Amount")
F2: (Continued from Footnote 1) plus one non-tradeable contractual contingent value right ("CVR" and each CVR together with the Closing Amount, the "Offer Price"), which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement (the "CVR Agreement") on or prior to December 31, 2027 (the "Milestone").
F3: Upon the terms and subject to the conditions set forth in the Merger Agreement (a) each outstanding option to purchase Shares (each, a "Company Option") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an "In the Money Option"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an "Out of the Money Option")
F4: (Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect.
F5: Each restricted stock unit represents a contingent right to receive one Share.
F6: Pursuant to the terms of the Merger Agreement, (a) each outstanding restricted stock unit (each, a "Company RSU") that was granted prior to the date of the Merger Agreement, and each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as an "Accelerated 2023 RSU," was canceled and converted into the right to receive (1) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such Company RSU immediately prior to the Effective Time multiplied by (y) $42.00 and (2) one CVR for each Share subject to such Company RSU immediately prior to the Effective Time; and (b) each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as a "Cancelled 2023 RSU" was canceled and had no further force or effect.
F7: Not applicable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 20, 2026 Filed Aug 21, 2026 23:08 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 375,000 | $0.00 Strike: $1.52 | $0.00 |
DisclosureSEC source: 0001610717-26-000383 · form4.xml · derivative · entry 1 Duncan Jason · CIK 0001741553 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 375,000 Underlying: Common Stock · 375,000 shares Expires 2036-08-20 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from August 20, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| January 08, 2026 Filed Jan 9, 2026 21:18 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 750,000 | $0.00 Strike: $2.33 | $0.00 |
DisclosureSEC source: 0001610717-26-000010 · form4.xml · derivative · entry 1 Duncan Jason · CIK 0001741553 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Stock · 750,000 shares Expires 2036-01-08 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 8, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 500,000 | Not disclosed Strike: $0.72 | Not disclosed |
DisclosureSEC source: 0000950170-25-079924 · ownership.xml · derivative · entry 4 Duncan Jason · CIK 0001741553 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2035-02-13 F4 · derivative.exercise_price: On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F3 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 13, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 400,000 | Not disclosed Strike: $0.72 | Not disclosed |
DisclosureSEC source: 0000950170-25-079924 · ownership.xml · derivative · entry 3 Duncan Jason · CIK 0001741553 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2033-12-11 F4 · derivative.exercise_price: On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from December 11, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 500,000 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-079924 · ownership.xml · derivative · entry 2 Duncan Jason · CIK 0001741553 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 500,000 shares Expires 2035-02-13 F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F3 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 13, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| May 28, 2025 Filed May 30, 2025 22:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 400,000 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-079924 · ownership.xml · derivative · entry 1 Duncan Jason · CIK 0001741553 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 400,000 shares Expires 2033-12-11 F2 · price: On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from December 11, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 400,000 | Not disclosed Strike: $1.69 | Not disclosed |
DisclosureSEC source: 0000950170-25-022316 · ownership.xml · derivative · entry 3 Duncan Jason · CIK 0001741553 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2033-12-11 F4 · derivative.exercise_price: Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. F3 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F2 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from December 11, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | Disposition to issuerStock Option (Right to Buy) · Derivative | 400,000 | Not disclosed Strike: $12.97 | Not disclosed |
DisclosureSEC source: 0000950170-25-022316 · ownership.xml · derivative · entry 2 Duncan Jason · CIK 0001741553 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 400,000 shares Expires 2033-12-11 F3 · price: On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F2 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from December 11, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:30 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $1.69 | $0.00 |
DisclosureSEC source: 0000950170-25-022316 · ownership.xml · derivative · entry 1 Duncan Jason · CIK 0001741553 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2035-02-13 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 13, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| December 11, 2023 Filed Dec 12, 2023 23:16 UTC | Neumora Therapeutics, Inc. NMRA · Entity 6115 | GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $12.97 | $0.00 |
DisclosureSEC source: 0001610717-23-000398 · form4.xml · derivative · entry 1 Duncan Jason · CIK 0001741553 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2033-12-10 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from December 11, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| March 02, 2023 Filed Mar 2, 2023 16:44 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | Disposition to issuerRestricted Stock Units · Derivative | 65,850 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-014741 · doc4.xml · derivative · entry 7 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 65,850 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one Share. F6 · price: Pursuant to the terms of the Merger Agreement, (a) each outstanding restricted stock unit (each, a "Company RSU") that was granted prior to the date of the Merger Agreement, and each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as an "Accelerated 2023 RSU," was canceled and converted into the right to receive (1) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such Company RSU immediately prior to the Effective Time multiplied by (y) $42.00 and (2) one CVR for each Share subject to such Company RSU immediately prior to the Effective Time; and (b) each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as a "Cancelled 2023 RSU" was canceled and had no further force or effect. F6 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, (a) each outstanding restricted stock unit (each, a "Company RSU") that was granted prior to the date of the Merger Agreement, and each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as an "Accelerated 2023 RSU," was canceled and converted into the right to receive (1) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such Company RSU immediately prior to the Effective Time multiplied by (y) $42.00 and (2) one CVR for each Share subject to such Company RSU immediately prior to the Effective Time; and (b) each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as a "Cancelled 2023 RSU" was canceled and had no further force or effect. F7 · derivative.expiration_date: Not applicable. Read SEC document |
| March 02, 2023 Filed Mar 2, 2023 16:44 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | Disposition to issuerStock Option (right to buy) · Derivative | 37,500 | Not disclosed Strike: $30.68 | Not disclosed |
DisclosureSEC source: 0001209191-23-014741 · doc4.xml · derivative · entry 6 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,500 shares Expires 2028-06-07 F3 · price: Upon the terms and subject to the conditions set forth in the Merger Agreement (a) each outstanding option to purchase Shares (each, a "Company Option") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an "In the Money Option"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an "Out of the Money Option") F4 · price: (Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect. F3 · derivative.exercise_date: Upon the terms and subject to the conditions set forth in the Merger Agreement (a) each outstanding option to purchase Shares (each, a "Company Option") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an "In the Money Option"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an "Out of the Money Option") F4 · derivative.exercise_date: (Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect. Read SEC document |
| March 02, 2023 Filed Mar 2, 2023 16:44 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | Disposition to issuerStock Option (right to buy) · Derivative | 23,700 | Not disclosed Strike: $34.88 | Not disclosed |
DisclosureSEC source: 0001209191-23-014741 · doc4.xml · derivative · entry 5 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,700 shares Expires 2031-01-20 F3 · price: Upon the terms and subject to the conditions set forth in the Merger Agreement (a) each outstanding option to purchase Shares (each, a "Company Option") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an "In the Money Option"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an "Out of the Money Option") F4 · price: (Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect. F3 · derivative.exercise_date: Upon the terms and subject to the conditions set forth in the Merger Agreement (a) each outstanding option to purchase Shares (each, a "Company Option") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an "In the Money Option"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an "Out of the Money Option") F4 · derivative.exercise_date: (Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect. Read SEC document |
| March 02, 2023 Filed Mar 2, 2023 16:44 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | Disposition to issuerStock Option (right to buy) · Derivative | 24,337 | Not disclosed Strike: $24.67 | Not disclosed |
DisclosureSEC source: 0001209191-23-014741 · doc4.xml · derivative · entry 4 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,337 shares Expires 2030-01-20 F3 · price: Upon the terms and subject to the conditions set forth in the Merger Agreement (a) each outstanding option to purchase Shares (each, a "Company Option") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an "In the Money Option"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an "Out of the Money Option") F4 · price: (Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect. F3 · derivative.exercise_date: Upon the terms and subject to the conditions set forth in the Merger Agreement (a) each outstanding option to purchase Shares (each, a "Company Option") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an "In the Money Option"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an "Out of the Money Option") F4 · derivative.exercise_date: (Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect. Read SEC document |
| March 02, 2023 Filed Mar 2, 2023 16:44 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | Disposition to issuerStock Option (right to buy) · Derivative | 10,063 | Not disclosed Strike: $24.04 | Not disclosed |
DisclosureSEC source: 0001209191-23-014741 · doc4.xml · derivative · entry 3 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,063 shares Expires 2029-01-21 F3 · price: Upon the terms and subject to the conditions set forth in the Merger Agreement (a) each outstanding option to purchase Shares (each, a "Company Option") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an "In the Money Option"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an "Out of the Money Option") F4 · price: (Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect. F3 · derivative.exercise_date: Upon the terms and subject to the conditions set forth in the Merger Agreement (a) each outstanding option to purchase Shares (each, a "Company Option") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an "In the Money Option"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an "Out of the Money Option") F4 · derivative.exercise_date: (Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect. Read SEC document |
| March 02, 2023 Filed Mar 2, 2023 16:44 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | Disposition to issuerStock Option (right to buy) · Derivative | 15,900 | Not disclosed Strike: $26.75 | Not disclosed |
DisclosureSEC source: 0001209191-23-014741 · doc4.xml · derivative · entry 2 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,900 shares Expires 2032-01-17 F3 · price: Upon the terms and subject to the conditions set forth in the Merger Agreement (a) each outstanding option to purchase Shares (each, a "Company Option") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an "In the Money Option"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an "Out of the Money Option") F4 · price: (Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect. F3 · derivative.exercise_date: Upon the terms and subject to the conditions set forth in the Merger Agreement (a) each outstanding option to purchase Shares (each, a "Company Option") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an "In the Money Option"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an "Out of the Money Option") F4 · derivative.exercise_date: (Continue from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was canceled without consideration, and had no further force or effect. Read SEC document |
| March 02, 2023 Filed Mar 2, 2023 16:44 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | OtherCommon Stock | 3,296 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-014741 · doc4.xml · nonDerivative · entry 1 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the "Merger Agreement"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation ("Parent"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee ("Guarantor"), and the Issuer, pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of March 2, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was canceled and converted into the right to receive $42.00 in cash, without interest (the "Closing Amount") F2 · kind: (Continued from Footnote 1) plus one non-tradeable contractual contingent value right ("CVR" and each CVR together with the Closing Amount, the "Offer Price"), which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement (the "CVR Agreement") on or prior to December 31, 2027 (the "Milestone"). F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the "Merger Agreement"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation ("Parent"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee ("Guarantor"), and the Issuer, pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of March 2, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was canceled and converted into the right to receive $42.00 in cash, without interest (the "Closing Amount") F2 · price: (Continued from Footnote 1) plus one non-tradeable contractual contingent value right ("CVR" and each CVR together with the Closing Amount, the "Offer Price"), which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement (the "CVR Agreement") on or prior to December 31, 2027 (the "Milestone"). Read SEC document |
| January 23, 2023 Filed Jan 23, 2023 17:10 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | SaleCommon Stock | 228 | $43.80 | $9,986.40 |
DisclosureSEC source: 0001209191-23-004451 · doc4.xml · nonDerivative · entry 1 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,146 F1 · shares: Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Represents 3,296 shares of common stock and 10,850 restricted stock units. Read SEC document |
| January 19, 2023 Filed Jan 20, 2023 16:05 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | SaleCommon Stock | 938 | $43.90 | $41,182.33 |
DisclosureSEC source: 0001209191-23-004223 · doc4.xml · nonDerivative · entry 1 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,374 F1 · shares: Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.90 to $43.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · balance_after: Represents 2,867 shares of common stock and 11,507 restricted stock units. Includes 381 shares of common stock acquired under the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan (the "ESPP") on November 30, 2022. Read SEC document |
| January 19, 2023 Filed Jan 25, 2023 20:09 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | GrantCommon Stock | 55,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-004950 · doc4.xml · nonDerivative · entry 1 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,146 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 25% of the shares on January 19, 2024, with the remainder vesting in equal installments every three months thereafter beginning on April 19, 2024 and ending on January 19, 2027. F2 · balance_after: Represents 3,296 shares of common stock and 65,850 restricted stock units. Read SEC document |
| January 19, 2023 Filed Jan 27, 2023 17:26 UTC Amendment | ALBIREO PHARMA, INC. ALBO · Entity 116015 | GrantCommon Stock | 55,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-005335 · doc4a.xml · nonDerivative · entry 1 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,146 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 25% of the shares on January 19, 2024, 6.25% of the shares every three months thereafter beginning on April 19, 2024 and ending on January 19, 2025, and 12.5% of the shares every three months thereafter beginning on April 19, 2025 and ending on January 19, 2026. F2 · balance_after: Represents 3,296 shares of common stock and 65,850 restricted stock units. Read SEC document |
| October 24, 2022 Filed Oct 25, 2022 16:00 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | SaleCommon Stock | 456 | $19.40 | $8,844.71 |
DisclosureSEC source: 0001209191-22-054490 · doc4.xml · nonDerivative · entry 3 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,931 F4 · shares: Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.2697 to $19.54, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. F6 · balance_after: Represents 724 shares of common stock and 14,207 restricted stock units. Read SEC document |
| October 24, 2022 Filed Oct 25, 2022 16:00 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | SaleCommon Stock | 96 | $19.54 | $1,875.61 |
DisclosureSEC source: 0001209191-22-054490 · doc4.xml · nonDerivative · entry 2 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,387 F1 · shares: Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F3 · balance_after: Represents 1,180 shares of common stock and 14,207 restricted stock units. Read SEC document |
| October 24, 2022 Filed Oct 25, 2022 16:00 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | SaleCommon Stock | 104 | $19.58 | $2,035.95 |
DisclosureSEC source: 0001209191-22-054490 · doc4.xml · nonDerivative · entry 1 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,483 F1 · shares: Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Represents 1,276 shares of common stock and 14,207 restricted stock units. Read SEC document |
| July 25, 2022 Filed Jul 25, 2022 16:12 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | SaleCommon Stock | 220 | $23.66 | $5,204.21 |
DisclosureSEC source: 0001209191-22-043100 · doc4.xml · nonDerivative · entry 4 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,587 F4 · shares: Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2021. F7 · balance_after: Represents 724 shares of common stock and 14,863 restricted stock units. Read SEC document |
| July 25, 2022 Filed Jul 25, 2022 16:12 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | SaleCommon Stock | 93 | $24.40 | $2,268.74 |
DisclosureSEC source: 0001209191-22-043100 · doc4.xml · nonDerivative · entry 3 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,807 F1 · shares: Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F6 · balance_after: Represents 944 shares of common stock and 14,863 restricted stock units. Read SEC document |
| July 22, 2022 Filed Jul 25, 2022 16:12 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | SaleCommon Stock | 238 | $24.45 | $5,819.10 |
DisclosureSEC source: 0001209191-22-043100 · doc4.xml · nonDerivative · entry 2 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,900 F4 · shares: Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2021. F5 · balance_after: Represents 724 shares of common stock and 15,176 restricted stock units. Read SEC document |
| July 22, 2022 Filed Jul 25, 2022 16:12 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | SaleCommon Stock | 106 | $24.68 | $2,615.79 |
DisclosureSEC source: 0001209191-22-043100 · doc4.xml · nonDerivative · entry 1 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,138 F1 · shares: Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.67 to $25.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · balance_after: Represents 962 shares of common stock and 15,176 restricted stock units. Includes 236 shares of common stock acquired under the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan (the "ESPP") on May 31, 2022. Read SEC document |
| April 25, 2022 Filed Apr 25, 2022 16:38 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | SaleCommon Stock | 91 | $33.40 | $3,039.41 |
DisclosureSEC source: 0001209191-22-025522 · doc4.xml · nonDerivative · entry 4 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,008 F3 · shares: Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F6 · balance_after: Represents 488 shares of common stock and 15,520 restricted stock units. Read SEC document |
| April 25, 2022 Filed Apr 25, 2022 16:38 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | SaleCommon Stock | 221 | $33.44 | $7,390.17 |
DisclosureSEC source: 0001209191-22-025522 · doc4.xml · nonDerivative · entry 3 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,099 F1 · shares: Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2021. F5 · balance_after: Represents 579 shares of common stock and 15,520 restricted stock units. Read SEC document |
| April 22, 2022 Filed Apr 25, 2022 16:38 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | SaleCommon Stock | 103 | $32.93 | $3,391.35 |
DisclosureSEC source: 0001209191-22-025522 · doc4.xml · nonDerivative · entry 2 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,320 F3 · shares: Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F4 · balance_after: Represents 488 shares of common stock and 15,832 restricted stock units. Read SEC document |
| April 22, 2022 Filed Apr 25, 2022 16:38 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | SaleCommon Stock | 240 | $33.07 | $7,936.80 |
DisclosureSEC source: 0001209191-22-025522 · doc4.xml · nonDerivative · entry 1 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,423 F1 · shares: Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2021. F2 · balance_after: Represents 591 shares of common stock and 15,832 restricted stock units. Read SEC document |
| January 24, 2022 Filed Jan 25, 2022 16:39 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | SaleCommon Stock | 1,176 | $24.94 | $29,334.50 |
DisclosureSEC source: 0001209191-22-004809 · doc4.xml · nonDerivative · entry 3 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,663 F5 · shares: Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2021. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.67 to $25.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. F7 · balance_after: Represents 488 shares of common stock and 16,175 restricted stock units. Read SEC document |
| January 24, 2022 Filed Jan 25, 2022 16:39 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | SaleCommon Stock | 96 | $25.09 | $2,408.54 |
DisclosureSEC source: 0001209191-22-004809 · doc4.xml · nonDerivative · entry 2 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,839 F1 · shares: Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F4 · balance_after: Represents 1,664 shares of common stock and 16,175 restricted stock units. Read SEC document |
| January 24, 2022 Filed Jan 25, 2022 16:39 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | SaleCommon Stock | 416 | $24.88 | $10,351.00 |
DisclosureSEC source: 0001209191-22-004809 · doc4.xml · nonDerivative · entry 1 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,935 F1 · shares: Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.7811 to $24.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · balance_after: Represents 1,447 shares of common stock and 16,488 restricted stock units. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 16:52 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | GrantStock Option (right to buy) · Derivative | 15,900 | $0.00 Strike: $26.75 | $0.00 |
DisclosureSEC source: 0001209191-22-004060 · doc4.xml · derivative · entry 2 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,900 Underlying: Common Stock · 15,900 shares Expires 2032-01-17 F3 · derivative.exercise_date: This option vests as to 25% of the shares on January 18, 2023, with the remainder vesting in equal installments every three months thereafter beginning on April 18, 2023 and ending on January 18, 2026. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 16:52 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | GrantCommon Stock | 10,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-004060 · doc4.xml · nonDerivative · entry 1 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,351 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 25% of the shares on January 18, 2023, with the remainder vesting in equal installments every three months thereafter beginning on April 18, 2023 and ending on January 18, 2026. F2 · balance_after: Represents 488 shares of common stock and 17,863 restricted stock units. Includes 196 shares of common stock acquired under the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan on November 30, 2021. Read SEC document |
| October 25, 2021 Filed Oct 25, 2021 18:30 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | SaleCommon Stock | 217 | $29.21 | $6,338.57 |
DisclosureSEC source: 0001209191-21-061556 · doc4.xml · nonDerivative · entry 2 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,355 F4 · shares: Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2021. F5 · balance_after: Represents 292 shares of common stock and 7,063 restricted stock units. Read SEC document |
| October 22, 2021 Filed Oct 25, 2021 18:30 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | SaleCommon Stock | 95 | $28.85 | $2,740.83 |
DisclosureSEC source: 0001209191-21-061556 · doc4.xml · nonDerivative · entry 1 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,572 F1 · shares: Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.8350 to $28.8974, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · balance_after: Represents 509 shares of common stock and 7,063 restricted stock units. Read SEC document |
| July 23, 2021 Filed Jul 26, 2021 16:05 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | SaleCommon Stock | 223 | $31.43 | $7,008.89 |
DisclosureSEC source: 0001209191-21-048160 · doc4.xml · nonDerivative · entry 2 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,667 F3 · shares: Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2021. F4 · balance_after: Represents 292 shares of common stock and 7,375 restricted stock units. Read SEC document |
| July 22, 2021 Filed Jul 26, 2021 16:05 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | SaleCommon Stock | 90 | $34.13 | $3,071.70 |
DisclosureSEC source: 0001209191-21-048160 · doc4.xml · nonDerivative · entry 1 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,890 F1 · shares: Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Represents 515 shares of common stock and 7,375 restricted stock units. Read SEC document |
| June 25, 2021 Filed Jun 28, 2021 16:01 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | Exercise / conversionStock Option (right to buy) · Derivative | 6,300 | $0.00 Strike: $24.67 | $0.00 |
DisclosureSEC source: 0001209191-21-043467 · doc4.xml · derivative · entry 8 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,337 Underlying: Common Stock · 6,300 shares Expires 2030-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option vested as to 25% of the shares on January 21, 2021, with the remainder vesting in equal installments every three months thereafter beginning on April 21, 2021 and ending on January 21, 2024, provided that the vesting of the option may be accelerated, in whole or in part, based on the achievement of certain pre-established company performance criteria, but in no event prior to January 21, 2021. Read SEC document |
| June 25, 2021 Filed Jun 28, 2021 16:01 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | SaleCommon Stock | 6,300 | $36.22 | $228,186.00 |
DisclosureSEC source: 0001209191-21-043467 · doc4.xml · nonDerivative · entry 5 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,980 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.01 to $36.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. F4 · balance_after: Represents 292 shares of common stock and 7,688 restricted stock units. Includes 131 shares of common stock acquired under the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan (the "ESPP") on May 31, 2021. Read SEC document |
| June 25, 2021 Filed Jun 28, 2021 16:01 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | Exercise / conversionCommon Stock | 6,300 | $24.67 | $155,421.00 |
DisclosureSEC source: 0001209191-21-043467 · doc4.xml · nonDerivative · entry 4 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,280 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 16:01 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | Exercise / conversionStock Option (right to buy) · Derivative | 863 | $0.00 Strike: $24.67 | $0.00 |
DisclosureSEC source: 0001209191-21-043467 · doc4.xml · derivative · entry 7 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,637 Underlying: Common Stock · 863 shares Expires 2030-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option vested as to 25% of the shares on January 21, 2021, with the remainder vesting in equal installments every three months thereafter beginning on April 21, 2021 and ending on January 21, 2024, provided that the vesting of the option may be accelerated, in whole or in part, based on the achievement of certain pre-established company performance criteria, but in no event prior to January 21, 2021. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 16:01 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | Exercise / conversionStock Option (right to buy) · Derivative | 9,137 | $0.00 Strike: $24.04 | $0.00 |
DisclosureSEC source: 0001209191-21-043467 · doc4.xml · derivative · entry 6 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,063 Underlying: Common Stock · 9,137 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option vested as to 25% of the shares on January 22, 2020 with the remainder vesting in equal installments every three months thereafter, beginning on April 22, 2020 and ending on January 22, 2023. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 16:01 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | SaleCommon Stock | 10,000 | $36.38 | $363,800.00 |
DisclosureSEC source: 0001209191-21-043467 · doc4.xml · nonDerivative · entry 3 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,980 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 16:01 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | Exercise / conversionCommon Stock | 863 | $24.67 | $21,290.21 |
DisclosureSEC source: 0001209191-21-043467 · doc4.xml · nonDerivative · entry 2 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,980 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 16:01 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | Exercise / conversionCommon Stock | 9,137 | $24.04 | $219,653.48 |
DisclosureSEC source: 0001209191-21-043467 · doc4.xml · nonDerivative · entry 1 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 23, 2021 Filed Apr 26, 2021 18:13 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | SaleCommon Stock | 222 | $32.32 | $7,175.04 |
DisclosureSEC source: 0001209191-21-028384 · doc4.xml · nonDerivative · entry 2 Duncan Jason · CIK 0001741553 · Chief Legal Officer and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,849 F3 · shares: Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2021. F4 · balance_after: Represents 161 shares of common stock and 7,688 restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.